ArticleQuantitative imaging in medicine and surgery2026
Performance of Liver Imaging Reporting and Data System (LI-RADS) nonradiation treatment response algorithm version 2024 on magnetic resonance imaging for transarterial chemoembolization plus systemic therapy in hepatocellular carcinoma.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The effectiveness of Liver Imaging Reporting and Data System treatment response algorithm version 2024 (LR-TRA v2024) in hepatocellular carcinoma (HCC) patients undergoing locoregional plus systemic combination therapy remains uncertain. We aimed to investigate the performance of LR-TRA v2024 on magnetic resonance imaging (MRI) in detecting residual HCC following transarterial chemoembolization (TACE) plus systemic therapy. Methods: This single-center retrospective study included consecutive adult patients who received TACE plus systemic therapy for HCC and subsequent surgical resection (July 2019 to November 2023). All contrast-enhanced preoperative MRIs were independently evaluated by three blinded radiologists for LR-TR, Liver Imaging Reporting and Data System treatment response (LR-TR) categories and two ancillary features. Postoperative pathology was used as the reference standard for residual tumors, which was further categorized as any (>0%) or major (>10%) residual tumors. When investigating the performances of LR-TR categories, the LR-TR Equivocal category was grouped into the LR-TR Viable category. The diagnostic performances were evaluated using positive predicting value (PPV) and negative predicting value (NPV). Results: Fifty-one patients (median age, 56 years; 45 males) with 63 HCCs were included. For the detection of any residual tumor, the per-lesion PPV and NPV of the LR-TR Viable category were 100.0% and 46.9%, respectively; the per-patient PPV and NPV were 100.0% and 45.5%, respectively. For the detection of major residual tumor, the per-lesion PPV and NPV of the LR-TR Viable category were 80.6% and 84.4%, respectively; the per-patient PPV and NPV were 82.8% and 86.4%, respectively. Conclusions: LR-TRA v2024 was effective in evaluating treatment response and detecting residuals of HCC to TACE plus systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.